Product Information
DEXTROAMP-AMPHETAMIN 30 MG TAB is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.2956 per EA under NDC 31722016401. Its NADAC has been published 259 times since Oct 20, 2021.
FDA first approved this application on Apr 22, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
DEXTROAMP-AMPHETAMIN 30 MG TAB
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfateStrength
7.5; 7.5; 7.5; 7.5 mg/1; mg/1; mg/1; mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722016401
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA213709FDA Approved
4/22/2021
TE Code
AB
On Market Since
5/10/2021
Pharmacological Classes
Price Statistics
The NADAC for DEXTROAMP-AMPHETAMIN 30 MG TAB has been published 259 times since Oct 20, 2021, and over the history we have for it it has declined 15.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2956 per EA |
|---|---|
| All-time high | $0.3587 (Aug 16, 2023) |
| All-time low | $0.2416 (Jul 17, 2024) |
| 52-week high | $0.3153 |
| 52-week low | $0.2956 |
| Median price | $0.3122 |
| Average price | $0.3116 |
| Largest weekly change | -26.9% (Nov 20, 2024) |
| Weeks tracked | 259 |
| Tracking since | Oct 20, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEXTROAMP-AMPHETAMIN 30 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMP-AMPHETAMIN 30 MG TAB, manufactured by Camber Pharmaceuticals Inc., is $0.2956 per EA (NDC 31722016401), effective Sep 30, 2026.
How has the price of DEXTROAMP-AMPHETAMIN 30 MG TAB changed over time?
Over the history we have for it, the NADAC for DEXTROAMP-AMPHETAMIN 30 MG TAB has declined 15.5%. It has been tracked across 259 weekly CMS publications since Oct 20, 2021.
What are the highest and lowest recorded NADAC prices for DEXTROAMP-AMPHETAMIN 30 MG TAB?
Since Oct 20, 2021, the NADAC for DEXTROAMP-AMPHETAMIN 30 MG TAB has ranged from a low of $0.2416 (Jul 17, 2024) to a high of $0.3587 (Aug 16, 2023), with a median of $0.3122 per EA.
Are there cheaper alternatives to DEXTROAMP-AMPHETAMIN 30 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of DEXTROAMP-AMPHETAMIN 30 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DEXTROAMP-AMPHETAMIN 30 MG TAB?
DEXTROAMP-AMPHETAMIN 30 MG TAB (NDC 31722016401) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.